Read this manager's filing book
Disclosed positions
STEMPOINT CAPITAL LP: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- TANGO THERAPEUTICS INC
- Ticker
- TNGX
- Class
- COM
- Reported value
- $38,231,574
- Reported amount
- 1,223,019
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001420506-26-001687Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| TANGO THERAPEUTICS INC | TNGX | COM | $38,231,574 | 1,223,019 | SH | None |
| ABIVAX SA | ABVX | SPONSORED ADS | $37,800,132 | 283,657 | SH | None |
| REVOLUTION MEDICINES INC | RVMD | COM | $29,954,125 | 159,943 | SH | None |
| ERASCA INC | ERAS | COM | $28,687,526 | 1,565,913 | SH | None |
| TYRA BIOSCIENCES INC | TYRA | COM | $20,210,163 | 632,754 | SH | None |
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $19,578,955 | 200,851 | SH | None |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $17,605,886 | 346,914 | SH | None |
| MINERALYS THERAPEUTICS INC | MLYS | COM | $16,260,468 | 602,686 | SH | None |
| BIOHAVEN LTD | BHVN | COM | $15,835,296 | 1,064,200 | SH | None |
| SURROZEN INC | SRZN | COM NEW | $13,786,568 | 602,798 | SH | None |
| KINIKSA PHARMACEUTICALS INTL | KNSA | ORD SHS CL A | $13,380,514 | 209,234 | SH | None |
| SCHOLAR ROCK HLDG CORP | SRRK | COM | $13,153,030 | 239,146 | SH | None |
| ALKERMES PLC | ALKS | SHS | $12,994,746 | 248,015 | SH | None |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | ORD SHS | $12,529,187 | 622,723 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $12,468,584 | 37,243 | SH | None |
| ROIVANT SCIENCES LTD | ROIV | SHS | $12,330,159 | 348,408 | SH | None |
| BIOAGE LABS INC | BIOA | COM | $11,376,831 | 464,171 | SH | None |
| CG ONCOLOGY INC | CGON | COM | $11,321,746 | 159,349 | SH | None |
| ORUKA THERAPEUTICS INC | ORKA | COM | $11,083,593 | 116,461 | SH | None |
| IMMUNOVANT INC | IMVT | COM | $10,654,585 | 276,527 | SH | None |
| CELCUITY INC | CELC | COM | $10,273,998 | 98,203 | SH | None |
| RELMADA THERAPEUTICS INC | RLMD | COM | $10,103,844 | 1,460,093 | SH | None |
| CLIMB BIO INC | CLYM | COM | $9,685,395 | 742,745 | SH | None |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $9,492,890 | 106,926 | SH | None |
| ZURA BIO LTD | ZURA | CLASS A ORD SHS | $8,072,469 | 1,368,215 | SH | None |
| INFLARX NV | Unresolved | COM | $7,231,291 | 3,228,255 | SH | None |
| AMYLYX PHARMACEUTICALS INC | AMLX | COM | $6,902,100 | 384,304 | SH | None |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $6,638,711 | 178,412 | SH | None |
| OVID THERAPEUTICS INC | OVID | COM | $6,502,491 | 2,417,283 | SH | None |
| EQUILLIUM INC | EQ | COM | $6,453,142 | 2,016,607 | SH | None |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $6,450,313 | 137,124 | SH | None |
| CYTOKINETICS INC | CYTK | COM NEW | $6,440,620 | 75,603 | SH | None |
| DAMORA THERAPEUTICS INC | DMRA | COM NEW | $5,623,206 | 216,194 | SH | None |
| INVENTIVA SA | IVA | ADS | $5,391,490 | 1,426,320 | SH | None |
| CENTURY THERAPEUTICS INC | IPSC | COM | $5,258,146 | 2,146,182 | SH | None |
| AURA BIOSCIENCES INC | AURA | COM | $5,071,388 | 714,280 | SH | None |
| EYEPOINT INC | EYPT | COM NEW | $4,840,135 | 338,471 | SH | None |
| ASSEMBLY BIOSCIENCES INC | ASMB | COM NEW | $4,681,987 | 170,378 | SH | None |
| WHITEHAWK THERAPEUTICS INC | WHWK | COM | $4,676,349 | 1,021,037 | SH | None |
| XENON PHARMACEUTICALS INC | XENE | COM | $4,591,887 | 76,075 | SH | None |
| UNIQURE NV | QURE | SHS | $4,058,577 | 88,115 | SH | None |
| COMPASS PATHWAYS PLC | CMPS | SPONSORED ADS | $4,029,481 | 284,769 | SH | None |
| AVALYN PHARMACEUTICALS INC | AVLN | COM SHS | $3,884,560 | 118,000 | SH | None |
| MAPLIGHT THERAPEUTICS INC | MPLT | COM | $3,831,511 | 106,906 | SH | None |
| ALUMIS INC | ALMS | COM | $3,819,611 | 135,736 | SH | None |
| AXSOME THERAPEUTICS INC. | AXSM | COM | $3,763,339 | 15,375 | SH | None |
| MONTE ROSA THERAPEUTICS INC | GLUE | COM | $3,715,765 | 153,544 | SH | None |
| ACADIA PHARMACEUTICALS INC | ACAD | COM | $3,622,125 | 143,167 | SH | None |
| SOLID BIOSCIENCES INC | SLDB | COM NEW | $3,584,212 | 358,780 | SH | None |
| PERSONALIS INC | PSNL | COM | $3,320,292 | 247,783 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 2 positions lack a resolved ticker and 11 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.